Licencing

Showing 6 posts of 6 posts found.

astrazeneca_building_white

AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development

UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …

AstraZeneca sells rights to anaesthetics products to Aspen for $520 million upfront

June 9, 2016
Research and Development, Sales and Marketing AstraZeneca, Licencing, anaesthetics, aspen, marketing agreement

UK drug firm AstraZeneca (LSE: AZN) on Thursday said it has agreed to sell rights for its anaesthetics portfolio to Aspen …

astrazeneca_plaque

AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America

June 2, 2016
Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales

UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …

ironwood_pharma

AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals

April 27, 2016
Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales

AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …

regeneron

Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology

April 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics

Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …

eli_lilly_logo

Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump

April 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis

Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …

Latest content